Skip to Main Content

Paper Details

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.
Res Sq
8
2021
B.1.1.7., COVA1-18, COVA1-18 neutralizing antibody, COVID-19, Coronavirus Disease, SARS, SARS-, SARS-CoV, SARS-CoV-2, Severe, Severe Acute Respiratory Syndrome coronavirus, Syrian hamsters, cynomolgus macaques, hACE2, lung lesions, lymphopenia, mice, patient, patients
Author NameAffiliation
Natalia A KuzminaIcahn School of Medicine at Mount Sinai
Raveen RathnasingheUniversity of Amsterdam, Amsterdam Institute for Infection and Immunity
David C MontefioriThe Scripps Research Institute
Ian A Wilson
Adolfo Garc??a-SastreIcahn School of Medicine at Mount Sinai
Adolfo Garc??a-SastreGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Michael SchotsaertIcahn School of Medicine at Mount Sinai
Michael SchotsaertUniversity of Maryland School of Medicine, Department of Microbiology and Immunology and Center for Vaccine Development and Global Health (CVD)
Lynda CoughlanUniversity of Texas Medical Branch at Galveston
Lynda CoughlanGalveston National Laboratory
Lynda CoughlanUniversity of Texas Medical Branch at Galveston
  • 1 - 11

Datasets

Release 1.2